US4031894A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bandage for transdermally administering scopolamine to prevent nausea
Assignee: Alza Corp
•
Filing: 1976-09-07
•
Granted: 1977-06-28
•
Expires: 1996-09-07
Abstract
Abstract Method and therapeutic system in the form of a bandage that administer scopolamine base transdermally in an initial pulse of 10 to 200 μg/cm 2 of skin that quickly brings the concentration of scopolamine in the plasma to a level at which emesis and nausea are inhibited without intolerable side effects, followed by a substantially constant dosage in the range of 0.3 to 15 μg/hr that holds said level. The bandage is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-scopolamine reservoir lamina that is the source of the constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-scopolamine adhesive layer that is the source of the pulse dose and the means by which the bandage is attached to the skin.
Inventors
- 👤 John Urquhart
- 👤 Santosh Kumar Chandrasekaran
- 👤 Jane Elizabeth Shaw
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 23:26
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61F; A61F13/00; A61F13/00051; A61F13/00063; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/46; A61K9/7092; A61F13/15; A61F13/53; A61F13/534; A61F13/84; A61F13/8405; A61F2013/00361; A61F2013/00902; A61F2013/00919; A61F2013/53445; A61F2013/8476; A61F2013/8479
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
192 words
A therapeutic system in the form of a bandage for administering scopolamine base through unbroken skin to inhibit emesis and nausea for a prolonged time period comprising a sandwich-type laminate of: (a) a backing lamina that is substantially impermeable to scopolamine base, one face of which forms the top of the bandage: (b) a scopolamine base reservoir lamina adjacent the opposite face of the backing lamina comprising i. (c) 0.2 to about 3 mg scopolamine base dispersed in a gelled mixture of (ii) mineral oil of about 10 to about 100 cp at 25° C., and polyisobutene; (c) a microporous membrane lamina adjacent and below the scopolamine reservoir lamina through which the scopolamine base is released from the reservoir lamina after the bandage is affixed to the skin at a substantially constant rate in the range of about 0.3 to about 15 μg/hr; and (d) a contact adhesive lamina adjacent and below the microporous membrane lamina by which said bandage is affixed to the skin comprising about 10 to about 200 μg scopolamine base per cm 2 effective surface area dispersed in a gelled mixture of said mineral oil and said polyisobutene.
Claim 2
Dependent Claim
192 words
A therapeutic system in the form of a bandage for administering scopolamine base through unbroken skin to inhibit emesis and nausea for a prolonged time period comprising a sandwich-type laminate of: (a) a backing lamina that is substantially impermeable to scopolamine base, one face of which forms the top of the bandage: (b) a scopolamine base reservoir lamina adjacent the opposite face of the backing lamina comprising i. (c) 0.2 to about 3 mg scopolamine base dispersed in a gelled mixture of (ii) mineral oil of about 10 to about 100 cp at 25° C., and polyisobutene; (c) a microporous membrane lamina adjacent and below the scopolamine reservoir lamina through which the scopolamine base is released from the reservoir lamina after the bandage is affixed to the skin at a substantially constant rate in the range of about 0.3 to about 15 μg/hr; and (d) a contact adhesive lamina adjacent and below the microporous membrane lamina by which said bandage is affixed to the skin comprising about 10 to about 200 μg scopolamine base per cm 2 effective surface area dispersed in a gelled mixture of said mineral oil and said polyisobutene.
Claim 3
Dependent Claim
48 words
The therapeutic system of claim 1 including (e) a strippable coating lamina adjacent and below the contact adhesive lamina that is substantially impermeable to the components of the contact adhesive lamina and is adapted to be stripped off the bandage before the bandage is affixed to the skin.
Claim 4
Dependent Claim
22 words
The therapeutic system of claim 1 wherein the effective surface area of the bandage is about 0.5 to 4 cm 2 .
Claim 5
Dependent Claim
31 words
The therapeutic system of claim 1 wherein the mineral oil constitutes 35% to 65% by weight of the mixture and the polyisobutene constitutes 35% to 65% by weight of the mixture.
Claim 6
Dependent Claim
40 words
The therapeutic system of claim 1 wherein the polyisobutene is a blend of a first polyisobutene having a viscosity average molecular weight of 35,000 to 50,000 and a second polyisobutene having a viscosity average molecular weight of 1,000,000 to 1,500,000.
Claim 7
Dependent Claim
44 words
The therapeutic system of claim 5 wherein the mineral oil constitutes 35% to 65% by weight of the mixture, the first polyisobutene constitutes 10% to 40% by weight of the mixture and the second polyisobutene constitutes 20% to 40% by weight of the mixture.
Claim 8
Dependent Claim
37 words
The therapeutic system of claim 1 wherein the microporous membrane lamina has a porosity of about 0.1 to 0.85, a tortuosity of about 1 to 10 and a thickness of about 10.sup. -3 to 10.sup. -2 cm.
Claim 9
Dependent Claim
15 words
The therapeutic system of claim 7 wherein the microporous membrane lamina is made of polypropylene.
Claim 10
Dependent Claim
30 words
The therapeutic system of claim 8 wherein the effective surface area of the patch is about 0.5 to 4 cm 2 and the microporous membrane lamina is made of polypropylene.
Claim 11
Dependent Claim
16 words
The therapeutic system of claim 9 wherein the backing lamina is made of aluminized polyethylene terephthalate.
Claim 12
Dependent Claim
53 words
The therapeutic system of claim 1 wherein said substantially constant rate is in the range of 5 to 15 μg/hr and said contact adhesive lamina comprises about 50 to about 150 μg scopolamine base per cm 2 of effective surface area dispersed in a gelled mixture of said mineral oil and said polyisobutene.
Claim 13
Dependent Claim
53 words
The therapeutic system of claim 1 wherein said substantially constant rate is in the range of 3 to 10 μg/hr and said contact adhesive lamina comprises about 50 to about 150 μg scopolamine base per cm 2 of effective surface area dispersed in a gelled mixture of said mineral oil and said polyisobutene.
References Cited (Backward Citations)
US3767786A
Cited
US3426754A
Cited
US3464413A
Cited
US3632740A
Cited
US3598123A
Cited
US3797494A
Cited
US3731683A
Cited
US3783869A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-06-27 | 1980-12-27 | 1981-06-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-06-27 | 1984-12-27 | 1985-06-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-06-27 | 1988-12-27 | 1989-06-28 | $7700.00 | Window Closed / Lapsed |